Collegium Pharmaceutical, Inc. $COLL Shares Bought by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management S.A. boosted its stake in Collegium by 161.6% in Q4 to 511,698 shares, representing 1.62% ownership worth about $23.7 million.
• Collegium missed Q4 estimates with EPS of $2.04 vs. $2.20 and revenue of $205.45M vs. $206.36M, though revenue was up 12.9% year-over-year and return on equity was 98.65%.
• Insiders sold sizable stakes (EVPs Scott Dreyer and David Dieter sold ~49,976 and ~13,976 shares respectively), while analysts maintain a consensus "Moderate Buy" with a $53.40 price target.

Assenagon Asset Management S.A. lifted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 161.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 511,698 shares of the specialty pharmaceutical company's stock after acquiring an additional 316,109 shares during the period. Assenagon Asset Management S.A. owned 1.62% of Collegium Pharmaceutical worth $23,692,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of COLL. Federated Hermes Inc. raised its holdings in shares of Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company's stock valued at $31,000 after buying an additional 350 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in Collegium Pharmaceutical by 137.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company's stock worth $60,000 after buying an additional 993 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company's stock worth $73,000 after buying an additional 2,190 shares in the last quarter. NewEdge Advisors LLC increased its position in Collegium Pharmaceutical by 304.6% in the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company's stock valued at $90,000 after acquiring an additional 2,294 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Collegium Pharmaceutical by 444.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,551 shares of the specialty pharmaceutical company's stock valued at $105,000 after acquiring an additional 2,899 shares during the period.

Collegium Pharmaceutical Stock Up 0.1%

Shares of COLL stock opened at $33.25 on Thursday. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $50.79. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57. The business's fifty day moving average is $42.44 and its 200-day moving average is $41.78. The stock has a market cap of $1.06 billion, a PE ratio of 19.44 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16). The firm had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The company's quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.77 EPS. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on COLL shares. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research note on Tuesday, February 10th. Needham & Company LLC restated a "buy" rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Barclays reduced their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an "overweight" rating for the company in a report on Friday, January 9th. Zacks Research cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings downgraded shares of Collegium Pharmaceutical from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus price target of $53.40.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the transaction, the executive vice president owned 71,770 shares of the company's stock, valued at $2,900,225.70. The trade was a 41.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP David Dieter sold 13,976 shares of the business's stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.